•  

Posts Tagged: Pfizer Inc.

Encycle Therapeutics working with major pharmaceutical companies to design rules for drugs meant to be swallowed

CQDM and MaRS Innovation investing in new Encycle project to determine rules for making peptide drugs orally bioavailable PHILADELPHIA (June 16, 2015) — FiercePharma has predicted that the pharmaceutical industry stands to lose $44 billion in drugs going off patent in 2015. The industry is searching for new therapeutics to replenish their pipelines while tackling existing and new drug receptor targets within the cell, improve patient care and lower administrative costs. In this context, drugs that can be orally swallowed, known as ... Read more

BioCentury features Encycle Therapeutics

Encycle Therapeutics, a MaRS Innovation start-up company from the University of Toronto, was featured in a BioCentury emerging company profile by Michael J. Haas. The company is currently raising a Series A financing round and employs eight people. Haas' profile, "Encycle: Oral Macrocycles," is available behind a pay wall on the BioCentury website. Here's a short excerpt: Macrocycle therapies can block protein-protein interactions that are undruggable with small molecules; however, oral availability and cell penetration remain key challenges. Encycle Therapeutics Inc.’s chemistry platform generates drug-like ... Read more

MaRS Innovation’s 2013 Top 10 List

2013 was an exceptional year for MaRS Innovation. Here are the top 10 news stories from our commercialization portfolio. 1. MaRS Innovation secures a $15 million CECR funding extension In January, MaRS Innovation was one of four Centres of Excellence for Commercialization and Research to be successfully extended by the Networks of Centres of Excellence of Canada. This achievement reflects and recognizes the quality of the startups and licensable technologies within the MaRS Innovation portfolio, as well as the rigour of its business model and the achievements of its ... Read more

MaRS Innovation and Pfizer fund Bio-Manufacturing Technology

Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership. Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area. This announcement was covered by BetaKit. His technology generates cell lines with improved protein production and survival properties, important in the ... Read more

MaRS Innovation launches streamlined funding program

Applications invited for MI’s Industry Access Program, which matches early-stage, high-potential technologies to partners and funding MaRS Innovation (MI) has launched a unique funding program to match researchers with industry partners while advancing early stage technologies: the MaRS Innovation Industry Access Program (MI-IAP). This program provides a simple mechanism to connect researchers with MI’s industry partners. The process and application form are intentionally brief to save researchers time and allow MI's partners to review a wide range of remarkable technologies within the Toronto academic ... Read more

Canadian biotech sector makes strong showing at BIO2013

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013. The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ... Read more

MaRS Innovation announces new strategic partnership with Pfizer

TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics. Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals. “There’s growing consensus that transferring technologies from the university lab ... Read more